Emraclidine vs NTX-253
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Muscarinic M4 receptor · full Schizophrenia pipeline
Emraclidine
Developed by AbbVie and partners
NCT05227703 · Phase 2 · completed
Participants were randomly assigned to emraclidine 15 mg, emraclidine 30 mg, or matching placebo and were double-blinded, with 130–131 participants per group. The primary clinical endpoint was not met: the Week 6 PANSS comparison was nonsignificant for both 15 mg versus placebo (p=0.2925) and 30 mg versus placebo (p=0.3914).
Next expected readout: February 2028 · NCT07145918 (registry estimate)
Reported efficacy
Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline through Week 6): Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline through Week 6): Emraclidine 15mg QD -18.5 score on a scale (95% CI -22 to -15) | Emraclidine 30mg QD -14.2 score on a scale (95% CI -17.5 to -10.8) vs Placebo -16.1 score on a scale (95% CI -19.4 to -12.8) (missed)
Result source: NCT05227703
NTX-253
Developed by Neurosterix Pharma Sàrl
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Emraclidine | NTX-253 |
|---|---|---|
| PANSS total, change | -14.2 vs -16.1+1.9 vs placeboNCT0522770327 other results
| —Not reported |
| CGI-S, change | -0.8 vs -0.8±0 vs placeboNCT0522770327 other results
| —Not reported |
| PANSS response | —Not reported | —Not reported |
| PSP, change | —Not reported | —Not reported |
| Relapse (% of patients) | —Not reported | —Not reported |
PANSS total, change
- Emraclidine
- -14.2 vs -16.1+1.9 vs placeboNCT05227703
27 other results
- -16.5 vs -13.5 NCT05227690
- -18.5 vs -16.1 NCT05227703
- -14.7 vs -13.5 NCT05227690
- -14.2 vs -16.1 NCT05227703
- -16.5 vs -13.5 NCT05227690
- -12.9 vs -14.7 NCT05227703
- -14.7 vs -13.2 NCT05227690
- -12 vs -12.8 NCT05227703
- -13.3 vs -12.1 NCT05227690
- -10 vs -11.2 NCT05227703
- -11.3 vs -10.3 NCT05227690
- -7.5 vs -8.5 NCT05227703
- -9 vs -8.7 NCT05227690
- -4.9 vs -5 NCT05227703
- -6.2 vs -5.2 NCT05227690
- -18.5 vs -16.1 NCT05227703
- -16.5 vs -14.7 NCT05227703
- -13.4 vs -12.8 NCT05227703
- -12.5 vs -11.2 NCT05227703
- -8.7 vs -8.5 NCT05227703
- -6.8 vs -5 NCT05227703
- -14.7 vs -13.5 NCT05227690
- -14 vs -13.2 NCT05227690
- -12.8 vs -12.1 NCT05227690
- -10 vs -10.3 NCT05227690
- -8.8 vs -8.7 NCT05227690
- -5.7 vs -5.2 NCT05227690
- NTX-253
- —Not reported
CGI-S, change
- Emraclidine
- -0.8 vs -0.8±0 vs placeboNCT05227703
27 other results
- -0.8 vs -0.8 NCT05227703
- -0.8 vs -0.7 NCT05227690
- -0.8 vs -0.7 NCT05227690
- -0.7 vs -0.8 NCT05227703
- -0.7 vs -0.7 NCT05227690
- -0.6 vs -0.7 NCT05227703
- -0.7 vs -0.5 NCT05227690
- -0.5 vs -0.6 NCT05227703
- -0.5 vs -0.5 NCT05227690
- -0.4 vs -0.4 NCT05227703
- -0.3 vs -0.4 NCT05227690
- -0.2 vs -0.2 NCT05227703
- -0.2 vs -0.2 NCT05227690
- -1.1 vs -0.8 NCT05227703
- -1.1 vs -0.8 NCT05227703
- -0.9 vs -0.8 NCT05227703
- -0.7 vs -0.7 NCT05227703
- -0.6 vs -0.6 NCT05227703
- -0.4 vs -0.4 NCT05227703
- -0.3 vs -0.2 NCT05227703
- -0.8 vs -0.7 NCT05227690
- -0.8 vs -0.7 NCT05227690
- -0.6 vs -0.7 NCT05227690
- -0.5 vs -0.5 NCT05227690
- -0.4 vs -0.5 NCT05227690
- -0.4 vs -0.4 NCT05227690
- -0.2 vs -0.2 NCT05227690
- NTX-253
- —Not reported
PANSS response
- Emraclidine
- —Not reported
- NTX-253
- —Not reported
PSP, change
- Emraclidine
- —Not reported
- NTX-253
- —Not reported
Relapse (% of patients)
- Emraclidine
- —Not reported
- NTX-253
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
NTX-253: no structured comparison results are available for Schizophrenia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Emraclidine: 4 of 4 rows · NTX-253: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Emraclidine |
|---|---|
| Dropout rate | 29%30 mg QDa NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2 show 5 more results—30mg QD NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2 28.5%15 mg QD NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2 —15mg QD NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2 28.7%30 mg once daily NCT05227690 · Phase 2 · registry result, not featured evidence 30.5%10 mg once daily NCT05227690 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3.1%30 mg QDa NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2 show 5 more results—30mg QD NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2 4.6%15 mg QD NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2 —15mg QD NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2 7.8%30 mg once daily NCT05227690 · Phase 2 · registry result, not featured evidence 4.7%10 mg once daily NCT05227690 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —30 mg QDa NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2 show 5 more results0.8%30mg QD NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2 —15 mg QD NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2 2.3%15mg QD NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2 0.8%30 mg once daily NCT05227690 · Phase 2 · registry result, not featured evidence 3.1%10 mg once daily NCT05227690 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 30mg QDa headache 13% (placebo 10.8%) dry mouth 5.3% (placebo 0.8%) anxiety 3.1% (placebo 3.1%) NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2 show 3 more results15mg QD headache 13.8% (placebo 10.8%) weight increased 8.5% (placebo 3.8%) constipation 4.6% (placebo 1.5%) NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2 30 mg once daily headache 13.2% (placebo 9.4%) dry mouth 9.3% (placebo 2.3%) dyspepsia 7.8% (placebo 3.1%) NCT05227690 · Phase 2 · registry result, not featured evidence 10 mg once daily weight increased 17.2% (placebo 8.6%) headache 14.1% (placebo 9.4%) somnolence 7% (placebo 4.7%) NCT05227690 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Emraclidine
show 27 more results
show 27 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Emraclidine's landscape · NTX-253's landscape